Post-earnings recap
Reported
Tue, Nov 6, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Est. EPS
—
Est. Rev
—
Impl. Move
—
CytomX Therapeutics reported a loss of $0.53 per share, but did not provide revenue figures or guidance. The stock reacted negatively, dropping 8.8%, indicating investor concerns about the company's performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.53 | N/A | — |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.